8-K filed September 9, 2024, 7:59 PM ET ticker BNGO CIK 0001411690

other material confidence high sentiment negative materiality 0.85

Bionano cuts workforce 45%, lowers revenue guidance to $32-36M, CFO departs

Bionano Genomics, Inc.

Reduction of ~84 employees (45% of workforce); expects $25-30M annual cost savings starting Q4 2024.
Revenue guidance reduced to $32-36M from $36-40M due to fewer OGM instrument placements.
CFO Gülsen Kama leaving effective Sep 18; CEO Erik Holmlin appointed principal financial officer.
Restructuring charges estimated at $0.5-1.0M, substantially complete by Oct 1, 2024.

item 2.05 item 5.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001140361-24-040508
form_type: 8-K
ticker: BNGO
cik: 0001411690
company_name: Bionano Genomics, Inc.
filed_at: 2024-09-09T23:59:59+00:00
discovered_at: 2026-05-14T18:03:12.967294+00:00
generated_at: 2026-05-31T05:52:31.010645+00:00
sec_items: ["2.05", "5.02", "7.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001140361-24-040508
json_url: https://secwatch.observer/filing/0001140361-24-040508.json
markdown_url: https://secwatch.observer/filing/0001140361-24-040508.md
text_url: https://secwatch.observer/filing/0001140361-24-040508.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036124040508/0001140361-24-040508-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036124040508/ny20035639x1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

R. Erik Holmlin

Principal Financial Officer

BNGO · Bionano Genomics, Inc.

Effective: 2024-09-18
Filed: September 9, 2024, 7:59 PM ET

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

Departed

Gülsen Kama

Chief Financial Officer

BNGO · Bionano Genomics, Inc.

Effective: 2024-09-18
Filed: September 9, 2024, 7:59 PM ET

the role of our Chief Financial Officer, Gülsen Kama, was impacted and Ms. Kama will no longer be employed with the Company effective September 18, 2024.

Appointed (interim)

Mark Adamchak

Principal Accounting Officer

BNGO · Bionano Genomics, Inc.

Effective: 2024-09-18
Filed: September 9, 2024, 7:59 PM ET

Mark Adamchak, Vice President of Accounting & Finance was appointed to serve as the principal accounting officer of the Company, effective September 18, 2024.

Source-grounded claims

7ccb6742ee

R. Erik Holmlin was appointed as Principal Financial Officer at Bionano Genomics, Inc..

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

880ceba24c

Gülsen Kama departed as Chief Financial Officer at Bionano Genomics, Inc..

the role of our Chief Financial Officer, Gülsen Kama, was impacted and Ms. Kama will no longer be employed with the Company effective September 18, 2024.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

ac0cc07b46

Mark Adamchak was appointed as Principal Accounting Officer at Bionano Genomics, Inc..

Mark Adamchak, Vice President of Accounting & Finance was appointed to serve as the principal accounting officer of the Company, effective September 18, 2024.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

Comparable filings

LIXT

Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board

LIXTE BIOTECHNOLOGY HOLDINGS, INC. June 1, 2026, 8:55 AM ET other_material Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: other_material similar materiality

This filing

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

Comparable filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

Comparable filing

John W. Heilshorn, Aaron Spool, Michael Faber, John Ziegelman and Jay Gettenberg (collectively, the “Directors”) were appointed to the board of directors of the Company (the “Board”).

Filing page SEC filing

ELOX

Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors

Eloxx Pharmaceuticals, Inc. June 1, 2026, 7:00 AM ET other_material Items 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

Comparable filing

the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board

Filing page SEC filing

FDXF

FedEx Freight completes spin-off from FedEx; $600M drawn, new board and executives appointed

FedEx Freight Holding Company, Inc. June 1, 2026, 6:46 AM ET other_material Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

Comparable filing

each of John A. Smith, R. Brad Martin, Jeffrey A. Davis, Donald E. Frieson, Stephen E. Gorman, Robert A. King, Cindy J. Miller, Amy J. Salcido, and Samantha M. Smith was appointed to the Board

Filing page SEC filing

FXAC

FortuneX Acquisition closes IPO of 8.625M units at $10/unit, raising $86.25M gross

FortuneX Acquisition Corp May 29, 2026, 5:32 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

Comparable filing

Effective May 19, 2026, in connection with the effectiveness of the Company’s Registration Statement, Becky Fallon, Sean Michael Deegan, and Robert Labbe became members of the board of directors (the “Board”) of the Company.

Filing page SEC filing

CWBHF

Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment

Charlotte's Web Holdings, Inc. June 1, 2026, 5:13 PM ET other_material Items 5.02, 5.07, 8.01

same fact type: executive_change same SEC item: 5.02 same event type: other_material similar materiality

This filing

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

Comparable filing

Effective May 28, 2026 (the “Effective Date”), the board of directors of Charlotte’s Web Holdings, Inc. (the “Company”), appoint James Jeffery Raborn to the Company’s board of directors

Filing page SEC filing

ENS

EnerSys realigns to three segments, names presidents for NIS, IMS, PPS

EnerSys May 28, 2026, 4:15 PM ET other_material Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: other_material

This filing

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

Comparable filing

As a result of the Company's Segment Realignment there will be a change in executive titles as follows: • Keith D. Fisher – President, Network & Infrastructure Solutions • Chad C. Uplinger – President, Industrial Mobility Solutions • Mark E. Matthews – Chief Technology Officer and President, Precision Power Solutions

Filing page SEC filing

CRMT

America's Car-Mart forms special committee for strategic alternatives; appoints new independent director

AMERICAS CARMART INC May 29, 2026, 5:30 PM ET other_material Items 1.01, 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material

This filing

On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024

Comparable filing

On May 22, 2026, the Board increased the size of the Board from nine members to ten members and appointed Adam Paul as an independent director, effective immediately.

Filing page SEC filing

Source: SEC EDGAR

accession 0001140361-24-040508

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.